MC
Therapeutic Areas
SOPHiA GENETICS Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SOPHiA DDM™ Dx HRD Solution | Homologous Recombination Deficiency in Cancer | Commercial |
| SOPHiA DDM™ Dx Solid Tumor Solution | Pan-Cancer Solid Tumor Profiling | Commercial |
| SOPHiA DDM™ Dx Myeloid Solution | Myeloid Blood Cancers | Commercial |
| SOPHiA DDM™ Dx Hereditary Cancer Solution | Inherited Cancer Risk | Commercial |
| SOPHiA DDM™ Dx RNAtarget Oncology Solution | Gene Fusions & Expression in Cancer | Commercial |
| SOPHiA DDM™ for Radiomics | Quantitative Imaging Analysis (e.g., Lung Cancer) | Development |
| SOPHiA DDM™ for Multimodal | Integrated Multi-Omics & Imaging Analysis | R&D |
| MSK-ACCESS® powered with SOPHiA DDM™ | Liquid Biopsy for Cancer | Commercial |
Leadership Team at SOPHiA GENETICS
DJ
Dr. Jurgi Camblong
Chief Executive Officer & Co-Founder
DP
Dr. Pierre Hutter
Chief Scientific Officer & Co-Founder
RR
Ruth-Anne Renaud
Chief Financial Officer
KP
Kevin Puylaert
Chief Commercial Officer
PD
Prof. Dr. med. Peter Bauer
Chief Genomic Officer